Last reviewed · How we verify
NCT05514184: PLAFOND
Plant-Focused Nutrition in Patients With Diabetes and Chronic Kidney Disease
NA trial testing PLAFOND diet in Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM) in 120 participants. Enrolling by invitation.
30 March 2026
Quick facts
| Lead sponsor | University of California, Irvine |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 1 October 2023 |
| Primary completion | 30 March 2026 |
| Estimated completion | 30 September 2026 |
| Sites | 2 locations across United States |
Drugs / interventions tested
- PLAFOND diet
Conditions studied
- Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM) — all drugs for Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM) →
- CKD Stage 3 — all drugs for CKD Stage 3 →
- CKD Stage 4 — all drugs for CKD Stage 4 →
- CKD Stage 5 — all drugs for CKD Stage 5 →
Sponsor
University of California, Irvine
Who can join
18 and older, any sex, with Chronic Kidney Disease (CKD) With Diabetes Mellitus (DM) or CKD Stage 3. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this pilot clinical trial, the investigators will recruit and randomize 120 patients with diabetes mellitus and chronic kidney disease (CKD/DM) stages 3 to 5 to a patient-centered and flexible Plant-Focused Nutrition in Diabetes (PLAFOND) diet with \>2/3 plant-based sources, which will be compared with a standard-of-care CKD diet, which is usually a low-potassium and low-salt diet, over a 6-month period. Through this study, the investigators will determine whether the plant-focused diet intervention is feasible for patient adherence, whether this diet is safe by avoiding malnutrition, frailty, and high potassium or glucose blood levels, and whether patient reported outcomes are favorably impacted.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Emerging Preventive Strategies in Chronic Kidney Disease: Recent Evidence and Gaps in Knowledge.
Pradhan N, Dobre M. · · 2023 · cited 7× · PMID 38038822 · DOI 10.1007/s11883-023-01172-5
Verify or expand the search:
- PubMed search for NCT05514184
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other University of California, Irvine trials
Trials by the same sponsor.
- NCT06952725 — Chatbot for Online Support Groups to Treat Tobacco Addiction · NA · not yet recruiting
- NCT07167862 — Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound · Phase 4 · not yet recruiting
- NCT07527325 — Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma · Phase 2 · not yet recruiting
- NCT07391891 — Musical Mindfulness for Pain in the ED Waiting Room · NA · not yet recruiting
- NCT07209917 — Secondary Cervical Cancer Prevention of Vulnerable Women With HPV and HIV Co-infection in India · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05514184 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of California, Irvine
- Last refreshed: 3 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05514184.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing